Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...
A University of Cambridge-led study identifies the protein interferon gamma (IFN-γ) as a potential biomarker for Long COVID fatigue and highlights an immunological mechanism underlying the ...
Recent insights reveal the potential role of interferon (IFN) signaling in the pathogenesis of OPLL, particularly the type I IFN pathway, which is known to play a role in innate immune responses ...
Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized that "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique ...
Their findings show that these cells greatly increase in number when exposed to the cytokine interferon- (IFN ), presenting a promising target for therapeutic strategies. Researchers from the ...
The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...
Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...
St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback